Literature DB >> 640751

Modification of prostaglandin and thromboxane release by immunological sensitisation and successive immunological challenges from guinea-pig lumg.

J R Boot, A F Cockerill, W Dawson, D N Mallen, D J Osborne.   

Abstract

The release of prostaglandins (PGs) and thromboxanes (Txs) from perfused guinea pig lungs was investigated during different immunological states. The major product released from normal lungs perfused with exogenous arachidonic acid was 6-oxo-PGF1a. The procedure of sensitisation to specific antigen resulted in an increase in the release of 15-oxo-13,14-dihydro-TxB2 and a decrease in the release of 6-oxo-PGF1a- and 6,15-dioxo-13,14-dihydro-PGF1a from lungs perfused with arachidonic acid. The relative amount of 15-oxo-13,14-dihydro-TxB2 released progressively increased with the number of immunological challenges with both exogenous and endogenously derived substrate, arachidonic acid. This change in response to successive immunological challenges may represent a protective mechanism to prevent parent Txs and PGs entering the systemic circulation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 640751     DOI: 10.1159/000232097

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  3 in total

1.  Sequential histamine inhalations cause increased bronchial histamine reactivity in guinea pigs: role of platelets, thromboxanes and prostacyclin.

Authors:  W Dorsch; C Hintschich; J Neuhauser; J Weber
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-09       Impact factor: 3.000

2.  Allergen tachyphylaxis of guinea pigs in vivo; a prostaglandin E mediated phenomenon?

Authors:  W Dorsch; L Frey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981       Impact factor: 3.000

3.  Differential release of eicosanoids by bradykinin, arachidonic acid and calcium ionophore A23187 in guinea-pig isolated perfused lung.

Authors:  Y S Bakhle; S Moncada; G de Nucci; J A Salmon
Journal:  Br J Pharmacol       Date:  1985-09       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.